

To whom it may concern:

February 14, 2014

Kowa Company Ltd.

Nissan Chemical Industries, Ltd.

Bringing patent infringement actions concerning generic drugs of "LIVALO," a therapeutic agent for hypercholesterolemia (the third report)

As the generic drug marketing authorization holders started manufacturing and selling generic drugs of "LIVALO," the therapeutic agent for hypercholesterolemia (non-proprietary name; pitavastatin calcium), manufactured and sold by Kowa Company Ltd. (Head office: Naka-ku, Nagoya-shi; President and Representative Director: Yoshihiro Miwa, hereinafter "Kowa" ) after their respective NHI price listings on December 13, 2013, Kowa and Nissan Chemical Industries, Ltd. (Head office: Chiyoda-ku, Tokyo; President and Representative Director: Kojiro Kinoshita, hereinafter "Nissan Chemical") intend to bring legal actions against the generic drug marketing authorization holders under Kowa's or Nissan Chemical's intellectual property rights concerning "LIVALO" (hereinafter "Intellectual Property Rights") after having investigated their infringement upon the Intellectual Property Rights.

This time, Nissan Chemical filed complaints dated February 13, 2014 against Yoshindo Inc., Nissin Pharmaceutical Co., Ltd., and Nippon Chemipharm Co., Ltd., with Tokyo District Court seeking injunctive relief to cease and desist from infringing upon the patent rights relating to a certain crystal form of the API of "LIVALO" owned by Nissan Chemical (hereinafter "Patent Rights").

As announced earlier, Nissan Chemical had already filed complaints dated December 25, 2013, and January 15, 2014 against the entities below which are generic drug marketing authorization holders of "LIVALO," with Tokyo District Court seeking injunctive relief to cease and desist from infringing upon the Patent Rights.

Entities named in respective complaints of December 25, 2013:

Daito Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., Kobayashi Kako Co., Ltd., Meiji Seika Pharma Co., Ltd., Towa Pharmaceutical Co., Ltd., Tsuruhara pharmaceutical Co., Ltd., and Kaken Pharmaceutical Co., Ltd.

Entities named in respective complaints of January 15, 2014:

Sagami Chemical Industry Co., Ltd., Nichi-Iko Pharmaceutical Co., Ltd., and

Kotobuki Pharmaceutical Co., Ltd.

The present action is therefore the third legal action.

Kowa and Nissan Chemical will in the future bring similar actions against any other entities as soon as their infringement upon the Intellectual Property Rights has been confirmed.

■ About “LIVALO”

“LIVALO” is a pharmaceutical whose API is invented and manufactured by Nissan Chemical, and Kowa is exclusively expanding its business globally (developing, manufacturing formulations, selling, and the business tie up with other companies, etc). In Japan, Kowa is to manufacture and sell the products under the brand names, “LIVALO Tablet 1mg; LIVALO Tablet 2mg; LIVALO Tablet 4mg/LIVALO OD Tablet 1mg; LIVALO OD Tablet 2mg; and LIVALO OD Tablet 4mg,” and Kowa Pharmaceutical Co. Ltd., is selling them. This pharmaceutical is ranked as a strong statin as a HMG-CoA reductase inhibitor which exhibits strong LDL cholesterol lowering activity. Besides its superior improvement effect against dislipidaemia, “LIVALO” is known by various supporting information to have characteristics, such as safety in long term use, less emergence of drug interactions, and clinical benefit with diabetic complication, etc., and is prescribed to many patients having dislipidaemia in Japan and also overseas.

Contact information for inquiries on the above	
Public Relations Department 2. Kowa Company. Ltd. TEL: 03-3279-7392	Corporate Planning Department Nissan Chemical Industries, Ltd. TEL: 03-3296-8320